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Abstract
Tetraspanin CD151 has been implicated in metastasis through forming complexes with different molecular partners. In this
study, we mapped tetraspanin web proteins centered on CD151, in order to explore the role of CD151 complexes in the
progression of hepatocellular carcinoma (HCC). Immunoprecipitation was used to isolate tetraspanin complexes from
HCCLM3 cells using a CD151 antibody, and associated proteins were identified by mass spectrometry. The interaction of
CD151 and its molecular partners, and their roles in invasiveness and metastasis of HCC cells were assayed through
disruption of the CD151 network. Finally, the clinical implication of CD151 complexes in HCC patients was also examined. In
this study, we identified 58 proteins, characterized the tetraspanin CD151 web, and chose integrin b1 as a main partner to
further investigate. When the CD151/integrin b1 complex in HCC cells was disrupted, migration, invasiveness, secretion of
matrix metalloproteinase 9, and metastasis were markedly influenced. However, both CD151 and integrin b1 expression
were untouched. HCC patients with high expression of CD151/integrin b1 complex had the poorest prognosis of the whole
cohort of patients. Together, our data show that CD151 acts as an important player in the progression of HCC in an integrin
b1-dependent manner.
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Introduction
The dismal prognosis of hepatocellular carcinoma (HCC) is
mostly attributed to high metastasis. This disease has attracted the
considerable attention of investigators from the bench to the clinic
[1,2]. Metastasis is a multi-step cascade involving migration of
tumor cells from the original site, evasion of host defense systems,
subsequent location to distant organs, and growth of secondary
tumors [3,4]. Throughout the cascade, from its original location to
distant sites,thereis constantinterplaybetween metastasizing tumor
cellsandthechangingmicroenvironment,leadingtothe breakdown
of normal cell adhesion which facilitates cell migration [5].
Integrins, which are composed of a non-covalent heterodimer of
a- and b-subunits, mediate signals from the extracellular matrix
(ECM) that help to regulate cell migration, differentiation, cell
cycle progression, apoptosis, phagocytosis, ECM assembly, and
metalloproteinase activity [5]. Within the integrin family, integrin
b1 has been widely studied in the biology of solid tumors, as its
expression positively correlates with poor prognosis in a several
malignancies, including breast cancer [6] and HCC [7]. These
effects are mostly attributed to the binding of integrin b1t o
ligands, fibronectin, and laminin, as well as the modulation of
cytoskeleton-signaling associated with cell migration, ECM
assembly, and metalloproteinase activity [5]. However, our
previous study showed that high levels of integrin b1 expression
in HepG2 cells with low metastatic potential and a high
percentage of integrin b1- positive cells in most HCC samples
[8]. These results indicate that the metastatic potential of HCC
cells is not completely dependent on integrin b1 expression.
Tetraspanins (TM4SF) possess four transmembrane domains: a
small intracellular loop, intracellular N- and C-termini with short
cytoplasmic tails, and two extracellular loops, the larger of which
contains a distinctive pattern of cysteine residues that helps to
define the family [9]. The most striking feature of tetraspanin
molecules is that they can assemble multimolecular signaling
complexes at the cell surface such as integrins, membrane
receptors, intracellular signaling molecules, other tetraspanins,
and immunoglobulin superfamily proteins at tetraspanin-enriched
microdomains (TEMs) to form ‘‘a tetraspanin web’’ [10,11]. This
‘‘tetraspanin web’’ can thus serve as molecular facilitators or
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24901organizers of multimolecular complexes on the cell surface
[9,12,13]. Recent studies have demonstrated that the great
heterogeneity in the composition of the ‘‘tetraspanin web’’,
and the dynamics of tetraspanin complexes, confer great
flexibility to tetraspanins that allow for specificity and functional
differences [14]. For example, CD82 can form complexes with
the GM2/GM3 heterodimer and inhibit cell motility through
the CD82-c-Met or integrin-c-Met pathway [15]. CD82
attenuates a6 integrin-mediated cellular morphogenesis through
modulation of integrin a6 signaling and internalization of
integrin a6 [16]. Hence, to uncover the functions of tetraspanin
proteins, it is critical to identify laterally interacting partner
proteins [12,13].
Tetraspanin CD151 (also named as SFA-1 and PETA-3), is an
important member of the tetraspanin family, and has been widely
studied in several malignant tumors [13,17,18,19]. Evidence has
demonstrated that CD151 forms complexes with integrins, c-
Met, other tetraspanins, and itself, and is implicated in
pathological processes associated with cancer progression
[12,20,21]. For example, modified HeLa cells overexpressing
CD151 have more migratory abilities than control cells
expressing little CD151 [22]. Other reports have shown that
antibodies against CD151 can inhibit cell migration [23].
Previously, we determined that CD151 was a crucial molecule
involved in tumor cell invasion [18], tumor neo-angiogenesis
[19], and epithelial-mesenchymal transition (EMT) [8]. We also
showed that it was associated with the progression and metastasis
of HCC by forming complexes with c-Met or integrin a6. This
suggests that CD151 is likely to participate in metastasis through
forming complexes with different molecular partners, which
contributes to heterogeneous characteristics in terms of the
aggressive potential and prognosis of HCC [24]. However, the
role of CD151 in malignant tumors is not simple. Overexpression
of CD151 significantly increases intercellular adhesiveness and
delays wound closure in a scratch assays [25,26]. Conversely,
downregulation of CD151 expression promotes invasiveness of
breast cancer cells [27]. Thus, CD151 is likely to possess diverse
and unpredictable functions in different cellular environments.
Thus, the ‘‘tetraspanin web’’ centered on CD151, and its
interaction in HCC remains to be investigated.
A more thorough description of the composition and organi-
zation of the tetraspanin web, and deeper exploration into the
interaction of tetraspanin complexes, are of importance in
understanding the function of these molecules. In the present
study, we performed proteomic analysis of CD151-containing
complexes by mass spectrometry (MS), and then evaluated the
interaction of CD151 and integrin b1 in vivo and in vitro. Finally, we
assayed the roles of CD151/b1-integrin complexes in the
prognosis of HCC patients.
Results
Characterization of the tetraspanin CD151 network in
HCC cells
With the knowledge of the structure and functional patterns of
tetraspanins, we mapped tetraspanin complexes centered on
CD151, to address the interaction of CD151 with its molecular
partner in HCC cells in the context of other regulatory
mechanisms. In present study, we chose HCCLM3 cells to do
the immuoprecipitation because HCCLM3 cells have the highest
expression of CD151 protein based on our previous study [18].
After isolation of CD151-containing complexes by immunopre-
cipitation, proteins were eluted using the stringent detergent,
Triton X-100, which dissociates tetraspanin-tetraspanin associations
[28]. Proteins were then resolved by SDS-PAGE (Fig. 1A), and
CD151-containing complexes were identified by mass spectrometry.
A common set of 58 proteins was obtained when the significance
threshold was set at p,0.05 (Table 1); identification of CD151 and
integrin b1 are shown in Fig. 1B and 1C. Bioinformatic analysis of
the enriched partners in various categories displayed an integrated
tetraspanin network centered on CD151 in HCC cells. We found
that 10of the 57 CD151-associated partner proteinsidentified, were
previously reported to directly or indirectly associate with CD151.
Based on the type of interaction, we classified three levels of
interactions in the tetraspanin network (Fig. 1D). As shown in
Fig. 1D, CD151 formed the first level of complexes with tetraspanin
partners integrin a3, a6, and b1 all of which were dependent on
direct interactions. We also observed seven functional complexes at
the second level, which indirectly interacted with CD151 (Fig. 1D).
Interestingly, 47 novel molecules were identified, which unknown
interacted with CD151 (Fig. 1D).
To analyze the role of molecular partners in the tetraspanin
network centered on CD151 in HCC cells, we performed gene
ontology (GO) analysis of the 57 molecular partner candidates.
They were classified according to categories of the ‘‘GO Biological
Process’’ as shown in Fig. 1E. Results revealed that molecular
partners included proteins involved in protein folding (HSP7C,
TCPB, RUVB2, COPA, TCPG, FKBP4 and GRP75), cell
migration (MOES, TSP1, c-MET, NRP1, ITA6, ITB1 and
GIPC1), cellular protein localization (IMA2, 1433B, SRP54,
COPA, IPO7, GRP75, CLH1 and GIPC1), protein transport
(IMA2, NU133, 1433B, SRP54, SC16A, COPA, IPO7, GRP75,
CLH1 and GIPC1), membrane organization (EHD4, HSP7C,
TSP1, LDLR, PACN2, COPA, CLH1), vesicle-mediated transport
(EHD4, HSP7C, TSP1, LDLR, PACN2, SC16A, COPA and
CLH1), regulation of apoptosis (TSP1, 1433B, AIFM1, HSP71,
GRP78, TRAF1, GRP75 and HSPB1), protein complex assembly
(SYEP, 1433B, SRP54, TRAF1, IPO7, FKBP4 and ELP1), nucleus
organization (NU133 and AIFM1), nucleocytoplasmic transport
(IMA2, NU133, IPO7 and GRP75), macromolecular complex
subunit organization (SYEP, NU133, 1433B, SRP54, TRAF1,
IPO7, FKBP4 and ELP1), integrin-mediated signaling pathway
(ITA3,ITA6 and ITB1) and regulationof cellular protein metabolic
processes (TSP1, GCN1L, IF2B1, 1433B, HSPB1 and GIPC1).
Among them, proteins related to protein folding and cell migration
represented the most abundant groups of proteins (Fig. 1E),
demonstrating that CD151 forms functional complexes with these
molecular partners to participate in biological processes of HCC,
including metastasis.
Consistent with previous results [8], we identified integrin a6
and b1 as molecular partners for CD151 in HCCLM3 cells and
HepG2 cells as well, but not in normal hepatocytes L-02
expressing little CD151 (Fig. 1F). To further explore the function
and interaction between CD151 and its partners in HCC cells, we
chose integrin b1 as a core partner for the follow reasons: (i)
among 57 tetraspanin partners, integrin b1 had the highest
Mascot score (Table 1), (ii) analysis of the ‘‘GO Biological Process’’
for mapping of the tetraspanin network, showed that proteins
associated with cell migration were the second most abundant
category of tetraspanin partners, of which integrin b1 played a
crucial role in cell migration, (iii) it is well documented that
integrin b1 is tightly associated with the progression of malignant
tumors, (iv) among 5 integrin subunits, integrin b1 expressed at
high level in HCCLM3 cells (Fig. S1). However, metastasis of
HCC is not completely dependent on integrin b1 expression, as
discussed in the ‘Introduction’. Therefore, we investigated the
interaction of the CD151/integrin b1 complex, and its role in
invasion and metastasis.
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in HCC cells
An immunofluorescence assay showed that CD151 and integrin
b1 were co-localized on the plasma membrane in HCCLM3 cells
(Fig. 2A). In line with our previous reports [8], the protein
expression of CD151 in HCC cells positively correlated to its
metastatic potential (Fig. 2B). Interestingly, all HCC cells used in
this study had high protein expression of integrin b1 (Fig. 2B).
Flow cytometry showed a high proportion of integrin b1-positive
cells in HCCLM3 cells, MHCC97H, MHCC97L, PLC/PRF/5,
Hep3B and HepG2 cells (Fig. 2C), indicating that the metastatic
potential of HCC cells is not associated with the percentage of
integrin b1-positive cells. The expression of CD151 or integrin b1
in HCCLM3-shRNA was downregulated at both the protein and
mRNA levels compared to parental cell lines (Fig. 2D and E).
As expected, the level of integrin b1 expression remained
unchanged in shRNA-CD151-HCCLM3 cells, and vice versa
(Fig. 2D and E), suggesting that the expression of integrin b1i s
independent of that of CD151.
CD151 increases invasion and mobility of HCC cells in an
integrin b1-dependent manner
Invasion assays were used to investigate the interaction of the
CD151/integrin b1 complex and itsrole inthe invasivenessofHCC
cells. Results showed that the number of invaded HCCLM3-mock
cellswere40610,significantlyhigher thanthoseofshRNA-CD151-
HCCLM3 (2268) and shRNA-integrin b1-HCCLM3 (2069) cells
(Fig. 3A and B). After transfection of CD151 cDNA into HepG2
cells, the number of invaded HepG2-CD151 cells was higher than
that of HepG2-mock cells (3268 verse 1665). Of note, when
CD151/integrin b1expressioninHepG2-CD151cellswassilenced,
the number of invaded cells markedly decreased (1765a n d1 5 66,
Figure 1. Identification of tetraspanin CD151 network and functional analysis. CD151-containing complexes were solubilized using the
mild detergent, Brij97, and were isolated by immunoprecipitation using specific CD151 mAbs. Associated proteins were eluted using Triton X-100 and
separated by SDS-PAGE (A). After in-gel trypsin digestion of proteins, the resulting peptides were analyzed using LC-MS/MS (B and C). The peptides
were separated by nano-HPLC. Total ion count was measured and visualized on a chromatogram (upper panel). At a precise time (e.g. 55.33 min for
CD151 and 67.18 min for integrin b1, dotted straight line), the mass spectrum obtained is shown (middle panel) in which a parent ion can be selected
(e.g. m/z=643.3489 for CD151 and 1010.0838 for integrin b1, black arrow). Fragmentation of that parent ion led to MS/MS spectrum generation
containing b and y ions, and thus sequence information of the parent ion (lower panel). The amino acid sequence can be deduced after searches in
the NCBI database using the program SEQUEST. The putative sequence of the peptide is shown with associated Xcorr and DCn. This peptide
sequence led to the identification of CD151 and integrin b1. These peptides were converted into a gene symbol and rearranged according to GO
functional enrichment provided by DAVID website. Then, the ‘‘tetraspanin CD151 web’’ was organized by the cytoscape (Ver: 2.6.2, http://www.
cytoscape.org/), searching target genes that interacted with CD151, and removing genes that were not contained in our target genes using a data
source (NCBI Entrez EUtilities Web Service Client) (D). Gene ontology analysis of the 57 molecular partners was performed. They were classified as 13
categories of biological processes including protein folding and cell migration (MOES, TSP1, c-MET, NRP1, ITA6, ITB1 and GIPC1) according to
categories of the ‘‘GO Biological Process’’ (E). Western blotting identified CD151 formed complexes with integrin a6 and b1 in HCCLM3 cells as well as
HepG2 cells, but not in normal hepatocytes L-02 (F).
doi:10.1371/journal.pone.0024901.g001
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Protein name Score Protein uniprot accession no. Theoretical molecular mass(Da) No. of peptides
Integrin b1 1037 P05556 88407 12
GRP-75 886 P38646 73635 16
Heat shock 70 kDa protein 8 560 P11142 70854 14
Integrin a3 542 P26006 118622 9
Cell proliferation-inducing gene 32 protein 497 P07814 170540 12
GRP-78 409 P11021 72288 9
p195 168 P46940 189134 4
HSP70-1/HSP70-2 168 P08107 70009 4
TP-alpha 156 P40939 82947 4
NAmPRTase 149 P43490 55487 4
CD151 128 P48509 28295 2
LDL receptor 114 P01130 95314 1
EF-1-alpha-1 109 P68104 50109 1
RuvB-like 2 106 Q9Y230 51125 3
Moesin 103 P26038 67778 2
UDPGDH 101 O60701 54989 2
PABP-1 100 P11940 70626 5
SEC16 homolog A 99 O15027 233373 2
RuvB-like 1 97 Q9Y265 50196 2
Neuropilin-1 90 O14786 103055 1
Integrin a6 88 P23229 126539 2
hnRNP Q 88 O60506 69560 2
Granulins 87 P28799 63500 1
Alpha-coat protein 87 P53621 138244 2
TIP-2 86 O14908 36027 1
CAD protein 86 P27708 242829 1
Restin 83 P30622 160891 1
PACSIN2 81 Q9UNF0 55704 4
LRP 130 81 P42704 157805 2
TCP-1-beta 77 P78371 57452 1
RP-A p70 70 P27694 68095 2
Nucleolin 66 P19338 76568 1
Cytochrome P450 27 63 Q02318 60196 1
Thrombospondin-1 61 P07996 129300 2
TCP-1-gamma 53 P49368 60495 1
HGF receptor 52 P08581 155427 2
HspB1 51 P04792 22768 1
Protein HS1 50 P27348 27764 3
TNFaR1 48 P50555 50696 2
Protein TFG 46 Q92734 43407 1
hnRNP K 45 P61978 50944 1
PAST homolog 4 44 Q9H223 61137 1
Importin-7 43 O95373 119440 2
LACS 3 43 O95573 80368 1
IMP-1 40 Q9NZI8 63417 1
Programmed cell death protein 8 40 O95831 66859 1
hnRNP M 38 P52272 77464 1
ELP1 37 O95163 150096 1
SRP54 36 P61011 55668 1
Importin subunit alpha-2 34 P52292 57826 1
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synergistic roles in the invasiveness of HCC cells.
Cell migration assays showed an apparent decrease in the
mobility of HCCLM3 cells transfected with shRNA-CD151 or
shRNA-integrin b1 (Fig. 3C). However, after transfection with the
CD151 plasmid, HepG2 cells had increased migratory capabilities.
Representative photography indicated accelerated closure in
HCCLM3-mock and HepG2-CD151 cells, compared to shRNA-
CD151-HCCLM3, shRNA-integrin b1-HCCLM3, HepG2-
CD151-shRNA-CD151, and HepG2-CD151-shRNA-integrin b1
cells (Fig. 3C). The aforementioned data indicate that CD151 likely
increases the invasion and mobility of HCC cells in an integrin b1-
dependent manner.
ELISA assays showed that the concentration of matrix metallo-
proteinase 9 (MMP9) in the supernatant of HCCLM3-mock cells
was significantly higher than that of shRNA-CD151-HCCLM3 and
shRNA-integrin b1-HCCLM3 cells (Fig. 3D). Similarly, after
transfection with the CD151 plasmid, HepG2-CD151 cells showed
increased secretion of MMP9. However, when HepG2-CD151 cells
were interfered with shRNA-CD151 or shRNA-integrin b1, they
showed decreased secretion of MMP9 (Fig. 3D). Under these
conditions, no significant changes in the MMP2 expression were
observed in the modified HCC cells interfered with shRNA-CD151
or shRNA-integrin b1, compared to parental cells (Fig. 3D). These
data indicate that CD151 forms a complex with integrin b1a n d
modulates MMP9 expression and secretion.
Interaction of proteins within the CD151/integrin b1
complex promotes HCC metastasis in vivo
To further investigate the interaction and role of the CD151/
integrin b1 complex in metastasis, we inoculated HCC cells
in liver parenchyma of nude mice. Tumor volumes of HCCLM3-
mock-derived xenografts were 1.9560.6 cm
3, which were signif-
icantly larger than those of HCCLM3-shRNA-CD151 (0.716
0.10 cm
3) and HCCLM3-shRNA-integrin b1 (0.5960.06 cm
3).
Tumor volumes of CD151-HepG2-derived xenografts were 1.896
0.6 cm
3, which were significantly larger than those of HepG2-
CD151-shRNA-CD151 and HepG2-CD151-shRNA- integrin
b1 (0.5160.05 cm
3 and 0.4760.04 cm
3, respectively, P,0.01;
Fig. 3E). Serial sections confirmed that pulmonary metastasis
rates, and metastatic tumor clusters per mouse were 100%
(5/5) and 210663 in the HCCLM3-mock group, but were
40% (2/5) and 124655 in the HCCLM3-shRNA-CD151
group, 40% (2/5) and 164646 in the HCCLM3-shRNA-
integrin b1 group, 60% (3/5), and 145643 in the CD151-
HepG2 group. There was no lung metastasis in the HepG2-mock,
HepG2-CD151-shRNA-CD151, and HepG2-CD151-vshRNA-
Integrinb1 groups (P,0.05; Fig. 3F).
Overexpression of the CD151-integrin b1 complex
correlates with poor prognosis of HCC patients
Here, we aimed to investigate the role of the CD151/integrin
b1 complex in a larger series of HCC patients. To this end, we
used immunohistochemistry to determine the expression of the
CD151/integrin b1 complex in consecutive tissue microarray
(TMA) slides consisting of 301 HCC and adjacent notumorous
samples (Fig. 4A–J). As reported in our previous study, CD151 was
mostly located on the membrane of tumor cells [8]. Strong positive
integrin b1 expression was observed in most HCC cells, as well as
the stroma fibroblasts and epithelial cells of the bile duct. Integrin
b1 expression in tumor cells was localized in the cytoplasm, and
had a diffuse or granular pattern (Fig. 4A–J). We then analyzed the
relationship between expression of the CD151/integrin b1
complex and clinicopathological features of HCC. HCC charac-
terized by microvascular invasion, large tumor (.5 cm) size, and
high TNM stage, were prone to higher expression of the CD151/
integrin b1 complex (Table 2). Kaplan-Meier analysis revealed
that patients with high levels of CD151 expression had a poorer
prognosis in terms of shorter OS and higher recurrence rates,
compared to those with low expression (Fig. 5A and B).
Expectedly, integrin b1 expression alone did not correlate to
prognosis in this cohort of patients (Fig. 5C and D). Interestingly,
patients were classified into four sub-groups according to their
CD151 and integrin b1 density. The sub-group with high
expression of the CD151/integrin b1 complex had the poorest
prognosis of the whole cohort of patients (Fig. 5E and F).
Univariate analysis revealed that CD151, microvascular invasion,
and TNM showed prognostic significance, with poor prognosis for
both OS and recurrence (Table 3). However, integrin b1
expression alone was not related to OS or recurrence. Multivariate
analysis showed that CD151 and CD151/integrin b1 complex
expression were independent predictors for OS or recurrence
(Table 3). The aforementioned data indicates that CD151
functions as a molecular facilitator in the progression of HCC in
an integrin b1-dependent manner.
Discussion
We previously identified tetraspanin CD151 as a key molecule
involved in the invasion and metastasis of HCC, most likely
through formation of functionally relevant complexes [8,18,19].
Here, we used large-scale proteomics screening techniques [29,30]
Protein name Score Protein uniprot accession no. Theoretical molecular mass(Da) No. of peptides
hnRNP H 33 P31943 49198 1
Extended-synaptotagmin-1 32 Q9BSJ8 122780 1
Hornerin 32 Q86YZ3 282228 1
SAPS domain family member 3 31 Q5H9R7 97608 1
Clathrin heavy chain 1 31 Q00610 191493 1
Nucleoporin Nup133 31 Q8WUM0 128898 1
p59 30 Q02790 51772 1
HsGCN1 30 Q92616 292558 1
doi:10.1371/journal.pone.0024901.t001
Table 1. Cont.
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network centered on tetraspanin CD151 in HCC cells.
An important result in this study was that CD151 organized ‘‘a
tetraspanin web’’ with several partners, including integrins a6 and
b1, c-Met, Moesin, thrombospondin-1 precursor, neuropilin 1,
and GIPC PDZ domain containing family, member 1, and served
as a molecular facilitator or adaptor for cell migration. Among
these molecules, the integrins were considered the most important
molecular partners for CD151 [9]. CD151 contains two
extracellular loops and two short cytoplasmic tails. The large
extracellular loop is necessary and sufficient for mediating the
stable interaction of CD151 with the integrin subunit [11,12].
Previous reports have revealed that CD151 can form a direct and
highly stoichiometric lateral complex with integrins a3, a6, a7, b1,
and b4, which are able to resist detergents such as digitonin and
Triton X-100 [23]. Anti-CD151 antibodies or CD151 mutants
can selectively inhibit integrin a3 and a6-dependent cell
migration, whereas upregulation of CD151 enhances experimental
metastasis of colon carcinoma and fibrosarcoma cells [31]. Mass
spectrometry data analysis showed that integrins a3, a6 and b1
serve as molecular partners for CD151. However, integrin a3
could not be identified by Western blot analysis after immuno-
Figure 2. Location and expression of CD151/integrin b1 complex in HCC cells. An immunofluorescence assay was performed. CD151 was
stained with red and integrin b1 was stain with green. CD151 and integrin b1 co-localized on the plasma membrane in HCCLM3 cells (A). Western
blotting revealed that the expression of CD151 in high metastatic HCCLM3 cells was highest and non-metastatic HepG2 cells presented the lowest
levels of CD151 among six HCC cells. The results also demonstrated high expression of integrin b1 in six HCC cells lines (B). Flow cytometry analysis
showed that the high proportion of integrin b1-positive cells were in six HCC cells (C). After transfection, HCCLM3-shRNA 2# was most efficient in
downregulating the expression of integrin b1 at both the protein and mRNA levels (D). The level of integrin b1 expression remained unchanged in
HCC interfered with CD151 shRNA, and vice versa (E).
doi:10.1371/journal.pone.0024901.g002
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showed that the number of invasive HCCLM3-mock and HepG2-CD151 cells were significantly higher than those of shRNA-CD151-HCCLM3, shRNA-
integrin b1-HCCLM3 cells and HepG2-CD151-shRNA-CD151, HepG2-CD151-shRNA-integrin b1, respectively (A and B). Wound healing assays revealed
an apparent decrease in the mobility of HCCLM3 cells transfected with shRNA-CD151 or shRNA-integrin b1. Similarly, disruption of CD151 or integrin
b1 in HepG2-CD151 cells, HepG2-CD151-shRNA-CD151 or shRNA-integrin b1 showed the impaired mobility (C). ELISA showed that the concentration
of MMP9 in the supernatant from HCCLM3-mock and HepG2-CD151 cells was significantly higher than that of shRNA-CD151-HCCLM3 cells, shRNA-
integrin b1-HCCLM3 cells and HepG2-CD151-shRNA-CD151 or shRNA-integrin b1, respectively (D). However, no significant changes of MMP2 were
observed in HCC cells after interference with CD151 or integrin b1 (D). After construction of metastasis model in situ, tumor volumes of HCCLM3-
mock-derived xenografts were significantly larger than those of HCCLM3-shRNA-CD151 and HCCLM3-shRNA-integrin b1 (E). The tumor volumes of
CD151-HepG2-derived xenografts were significantly larger than those of HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-integrin b1 (E). Serial
sections showed that the pulmonary metastasis rates and metastatic tumor clusters in the HCCLM3-mock group were higher than that of HCCLM3-
shRNA-CD151 group and the HCCLM3-shRNA-integrin b1 group. The pulmonary metastasis rates of CD151-HepG2 were markedly higher that of
HepG2-CD151-shRNA-CD151 and HepG2-CD151-vshRNA-Integrinb1 groups (F).
doi:10.1371/journal.pone.0024901.g003
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expression of integrin a3 in HCC cells [8,13]. It has been well
documented that the CD151/integrin complex acts as a functional
unit for modulation of physiological and pathological processes,
including cell migration, neurite outgrowth, and cell morphology
[11,13,32]. The identified tetraspanin web provided direct
evidence for our previous notion that CD151 formed a complex
with integrin a6, and induced epithelial–mesenchymal transition
in HCC cells [8]. Integrin b1 not only acts as an adhesive receptor
for laminins, but also as an intracellular signaling platform that
promotes cell migration and invasion [33]. Our results also
showed that the integrin b1 subunit often forms structural
complexes with the CD151 and integrin a subunit, in line with
a previous report [9]. An important partner in the tetraspanin web
is c-Met (hepatocyte growth factor receptor). Recent studies have
demonstrated the interaction between tetraspanins and c-Met.
Tetraspanin CD82 forms a complex with c-Met and inhibits
hepatocyte growth factor (HGF)-induced cancer cell migration by
inactivation of small GTP-binding proteins in the Rho family, via
c-Met adapter proteins [34]. CD82 also complexes with the
ganglioside GM2/GM3 heterodimer, and inhibits cell motility
through the CD82-c-Met or integrin-c-Met pathways [15]. CD151
can enhance receptor signaling through integrin b4-mediated
pathways and control c-Met-dependent neoplastic growth [35].
Our previous data also revealed that CD151 probably interacted
with c-Met and had an adverse effect on the prognosis of HCC
patients through HGF/c-Met pathways [18]. Importantly, the
proteins Moesin, thrombospondin-1 precursor, neuropilin 1, and
GIPC PDZ domain containing family, member 1, were observed
in the tetraspanin web. Recently, accumulating evidence has
demonstrated that these proteins interact with tetraspanins and
modulate cell migration. Upregulation of tetraspanin CD81
expression at the NK cell can induce phosphorylation of ezrin/
radixin/moesin proteins and lead to NK cell polarization, thereby
facilitating NK cell migration towards various chemokines/
cytokines [36]. The Ig superfamily proteins, EWIs, act as linkers
to connect tetraspanin-associated microdomains to the actin
cytoskeleton, to regulate cell motility and polarity via direct
interaction with ezrin/radixin/moesin (ERM) proteins [37].
However, the interaction between CD151 and these proteins,
and their roles in HCC cell migration remains to be determined.
In addition to having purely structural functions as organizers and
facilitators, CD151 also regulates various aspects of trafficking and
biosynthetic processing of associated receptors as identified in the
tetraspanin network, in line with a previous report [38]. Of the 57
proteins identified in Table 1, 47 have not previously been linked
to CD151. Regarding these potential CD151 partners, further
experiments are needed to confirm their direct association with
CD151, to assess the extent of this association, and to determine
functional implications.
Another implication about the characterized network centered
on CD151, is that it explains the functional complexity of CD151,
and provides a clue for uncovering the mystery. Traditionally,
overexpression of CD151 facilitates integrins and growth factor
receptors signals, activates Rac and Cdc42, and serves as a
transmembrane linker between extracellular integrin domains and
Figure 4. Expression of CD151/integrin b1 complex in HCC patients by immunohistochemistry. After identification by H&E staining (A1,
B1, C1, D1, E1, F1, G1, H1, I1, and J1), CD151 was mostly located on the membrane of tumor cells, with comparable variation (A2, B2, C2, D2, E2, F2,
G2, H2, I2, and J2) and strong integrin b1 expression in most HCC cells, stroma fibroblasts, and epithelial cells of the bile duct (A3, B3, C3, D3, E3, F3,
G3, H3, I3, and J3). A and B refer to adjacent nontumoral tissue. Representative tumor tissues are shown :C and D high expression of CD151 and
integrin b1, E and F high expression of CD151 and low expression of integrin b1, G and H high expression of integrin b1 and low expression of CD151,
I and J low expression of CD151 and integrin b1.
doi:10.1371/journal.pone.0024901.g004
Table 2. Correlations of CD151 and integrin b1 expression
with clinicopathological features of 301 HCCs.
variables CD151 staining P value Integrinb1 staining P value
high low high low
Sex
male 116 137 0.597 128 125 0.734
female 24 24 23 25
Age, year
$52 73 80 0.671 83 70 0.15
,52 67 81 68 80
HBsAg
positive 115 130 0.756 123 122 0.978
negative 25 31 28 28
Preoperative treatment
yes 63 62 0.254 67 58 0.315
no 77 99 84 92
Child -Pugh score*
A 140 160 1 150 150 1
B0 1 1 0
Serum AFP, ng/ml
#20 64 82 0.366 81 65 0.074
.20 76 79 70 85
Tumor number
single 115 145 0.046 129 131 0.63
multiple 25 16 22 19
Microvascular invasion
yes 16 6 0.01 16 6 0.028
none 125 155 135 144
Tumor encapsulation
complete 55 54 0.301 50 59 0.262
none 85 107 101 91
Tumor differentiation
I/II 39 50 0.544 42 47 0.504
III/IV 101 111 109 103
Tumor size (cm)
#5 71 102 0.027 78 95 0.04
.56 9 5 9 7 3 5 5
TNM stage
I/II 39 21 0.001 37 23 0.046
III 101 140 114 127
Abbreviations and Note: HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein;
TNM, tumor node metastasis; HBsAg, hepatitis B surface antigen; NS, not
significant; The X
2 test was used for comparison between groups. 50% for
CD151, Median of intensity for integrin b1 were used as the cut-off value.
*Fisher’s exact test.
doi:10.1371/journal.pone.0024901.t002
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24901Figure 5. Prognostic roles by Kaplan-Meier analysis. Kaplan-Meier analysis revealed that patients with high CD151 expression had poor
prognosis in terms of overall survival (A) and recurrence rate (B). However, no difference in overall survival (C) and recurrence rate (D) was observed
between high integrin b1 expression group and low expression group. Patients were classified into four groups according to their CD151 and integrin
b1 density: group I, high expression of both markers; group II, high expression of CD151 alone; group III, high expression of integrin b1 alone and
group IV, low expression of both markers. Kaplan-Meier analysis revealed that HCC patients with overexpression of CD151/ integrin b1 presented
with the worst overall survival (E) and the highest cumulative recurrence rate (F).
doi:10.1371/journal.pone.0024901.g005
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regulation of actin cytoskeleton, cell spreading, tumor cell motility,
and metastasis [26]. However, several papers have reported that
expression of CD151 has a negative influence on cell migration
and invasiveness [25,26,27]. The identified tetraspanin web
addressed these conflicting results. On one hand, CD151 can
form functional complexes with different partners and give rise to
different roles in cell adhesion, migration, and metastasis in
different cells. On the other hand, the molecular partners in the
tetraspanin web play an opposite role in the function of CD151.
For example, the low-density lipoprotein receptor precursor, one
of the molecular partners identified in this study, was found to
counteract the role of CD151 in the progression of HCC
(unpublished data). Another important result that arose from our
studies is that CD151 played a crucial role in cell migration,
invasiveness, and metastasis of HCC in an integrin b1-dependent
manner. Overexpression of CD151 has been associated with HCC
progression [8,18,19]. Recent studies have demonstrated that the
altered expression of b1 integrins in HCC, and overexpression of
b1 integrins correlate with aggressive phenotypes and metastasis of
HCC [7,39]. However, it is undeniable that HepG2 with very low
level of metastatic potential displays high level of b1 integrin, and
that a highly positive proportion of b1-integrin expression is
observed in most HCC samples [8]. Tetraspanins provide a
platform to organize proteins on the cell membrane, which has
great flexibility. Each tetraspanin may have specific partners for
interaction and can interact with different proteins and in that way
contribute to variability, and probably functional specificity, of the
complex [40]. Furthermore, the exposure of a CD151 epitope
involved in this binding is cell-type specific, and may vary
depending on the physiological and pathological status of the
tissues involved [21]. We noted that CD151 formed a functional
complex with integrin b1 in TEM. We postulated that integrin b1,
in concert with associated-CD151 molecules, might support HCC
progression, rather than individual integrin b1 molecules. In this
study, downregulation of CD151 in HCC cells had no effect on the
expression of integrin b1, and vice versa. When either CD151 or
integrin b1 was silenced, HCC cells with high expression of
CD151/integrin b1 complex displayed markedly impaired
motility, invasiveness, and metastasis both in vitro and in vivo.
However, integrin b1-silenced HepG2 cells with low levels of
CD151 expression had the same low mobile velocity and weak
invasion as that of the parental cell lines. Interestingly, re-
expressing CD151 in HepG2 cells reversed the mobile and
invasive defects. Moreover, CD151 or integrin b1-slienced HCC
cell with high expression of CD151/integrin b1 complex displayed
the markedly decreased secretion of MMP9, which was considered
as the most important molecule for matrix remodeling [41]. These
data indicate that loss of CD151 disrupts integrin b1 association
with tetraspanin-enriched microdomains, impairs integrin b1
internalization in cells migrating [31], and modulates the
extracellular matrix remodeling through influence of MMP9
secretion [19,20]. Even more importantly, we identified a role of
the CD151/integrin b1 complex in the clinical setting of HCCs.
HCC patients with high level of CD151/integrin b1 complex
expression had the worst prognosis of all populations examined. A
key property of integrins is that they can assume multiple
functional states. Integrins on normal cells are mostly inactive
Table 3. Univariate and multivariate analyses of factors associated with survival and recurrence.
factor Overall survival Cumulative Recurrence
Univariate Multivariate Univariate Multivariate
P HR 95% CI P P HR 95% CI P
Sex (male versus female) 0.835 NA 0.487 NA
Age (,52 versus .52 years) 0.234 NA 0.641 NA
HBsAg (negative versus positive) 0.563 NA 0.215 NA
Child-Pugh score (A versus B) 0.637 NA 0.626 NA
Serum AFP (.20 versus ,20 ng/mL) 0.037 1.335 0.978–1.822 NS 0.379 NA
Tumor size (.5 versus ,5 cm) 0.002 1.378 1.006–1.887 0.046 0.114 NA
Tumor number (multiple versus single) 0.003 1.637 1.098–2.440 0.015 0.083 NA
Microvascular invasion (yes versus no) ,0.001 1.886 1.114–3.191 0.018 0.018 1.917 1.053–3.488 0.033
Tumor encapsulation (none versus complete) 0.002 1.323 0.952–1.841 NS 0.087 NA
Tumor differentiation (III/IV versus I/II) 0.018 1.365 0.989–1.884 NS 0.061 NA
TNM stage (I/II versus III) ,0.001 NA 0.001 NA
CD151 density (,50% versus .50%) 0.002 0.698 0.512–0.951 0.023 ,0.001 0.555 0.396–0.777 0.001
Integrin b1 density (high versus low) 0.153 NA 0.054 NA
CD151/ Integrin b1 density* 0.002 0.003 ,0.001 ,0.001
I verse II 1.571 1.091–2.262 0.015 2.028 1.366–3.013 ,0.001
I verse III 0.847 0.515–1.392 NS 0.860 0.491–1.506 NS
I verse IV 0.718 0.438–1.174 NS 0.646 0.380–1.096 NS
The Cox proportional hazards regression model was used.
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HBsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; NS, not significant.
*Patients were classified into four groups according to their CD151 and Integrin b1 density: group I (n=93) had high expression of CD151 and Integrin b1, group II
(n=47) had high expression of CD151 but low Integrin b1 expression, group III (n=58) had high expression of Integrin b1 but low CD151 expression and group I V
(n=103) had low expression of CD151 and Integrin b1. Individual variables were first adopted for their prognostic significance by multivariate analysis, and then the
combination of CD151 and Integrin b1 was analyzed.
doi:10.1371/journal.pone.0024901.t003
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showed that CD151 could amplify the function of integrin a6 [8].
Therefore, b1 integrins expressed on HCC cells probably
harbored various levels of constitutive activity, and at the larger
scale, its role in the progression of HCC was activated by the
overexpression of CD151.
In conclusion, strong lateral CD151/integrin b1 complex is
functionally important, and CD151 serves as a key player in
integrin b1-dependent matrix remodeling, cell spreading, and
metastasis. Disassociation with CD151-integrin b1 complex is a
good choice for developing an anti-metastasis strategy for HCC.
Materials and Methods
Cell lines
Human HCC cell lines HCCLM3, MHCC97H, MHCC97L
(established in Liver Cancer Institute of Zhongshan Hospital,
Fudan University), PLC/PRF/5, Hep3B and HepG2 (American
Type Culture Collection, Manassas, VA), and normal hepatocytes
L-02 (Chinese Academy of Sciences, Shanghai) were used in this
study. Cells were maintained in a 37uC humidified incubator in
the presence of 5% CO2.
Immunoisolation of CD151-containing complexes and
in-gel tryptic digestion
To identify CD151-associated molecules, immunoprecipitation
was performed as previously described [20]. Briefly, 5610
8
HCCLM3 cells were lysed in 40 ml lysis buffer containing 10 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2,1 %B r i j
97,andproteaseinhibitorsfor2 hat4uC.Thelysatewascentrifuged
at 16,0006g for 15 min, and the supernatant was precleared with a
combination of protein A/G-agarose beads (Amersham Biosciences,
PA USA) precoated with BSA and goat serum (Sigma-Aldrich, MO,
USA) for 2 h at 4uC. Then, the lysate was incubated with a specific
antibody coupled to protein A/G-agarose beads for 2 h at 4uC.
Immobilized immune complexes were then washed four times with
lysisbuffer,elutedusing1%TritonX-100,andacetone-precipitated.
Proteins were resolved by 10% SDS-polyacrylamide gel electropho-
resis (PAGE) under non-reducing conditions, and detected by
immunoblot analysis using specific antibodies.
Gels were stained with colloidal Coomassie Blue (Bio-Rad, CA
USA), excised, and destained. Then, gel pieces were incubated in
100% acetonitrile for 10 min, dried, and incubated in 100 mM
ammonium bicarbonate containing 10 mMdithiothreitol(DTT)for
30 min at 56uC. After cooling to room temperature, gel pieces were
incubated with 55 mM iodoacetamide in 100 mM ammonium
bicarbonate for 20 min in the dark, at room temperature, washed
with 100 mM ammonium bicarbonate for 20 min, dehydrated with
100% acetonitrile (ACN), and dried. Then, gel pieces were digested
with 100 ng of trypsin and 25 mM ammonium bicarbonate (Roche
Applied Science, IN USA) overnight at 37uC. Peptides were
extracted successively with 50 ml of 5% formic acid for 15 min, and
100 ml of 100% acetonitrile for another 15 min at 37uC.
Two-dimensional liquid chromatography coupled with
tandem mass spectrometry (2D-LC-MS/MS) and data
analysis
Proteins were vacuum-dried and resuspended in 5% ACN
containing 0.1% formic acid. LC-MS/MS analyses were performed
using a Nano Aquity UPLC system (Waters, Milford, MA) coupled to
a LTQ Orbitrap XL mass spectrometer (Thermo Electron, Bremen,
Germany), and equipped with an online nanoelectrospray ion source
(Michrom Bioresources, Auburn, CA). The capillary column used in
this study was a BEH300 C18 reverse phase (75-mm inner diameter,
20 cm). To perform LC-MS/MS analysis, samples were injected into
the trap-column at a flow rate of 15 ml/min for 3 min, and
subsequently a 3-step linear 105-min gradient (flow rate, 300 nl/
min) from 5 to 80% acetonitrile in 0.1% (v/v) formic acid was
performed. All data were collected in centroid mode using a data-
dependent acquisition mode. After acquisition of a full MS scan (m/z:
400–2000 Da), in the first scan event, the three most intense ions
present above a threshold of 105 counts were subsequently isolated for
fragmentation (MS/MS scan). The collision energy for the MS/MS
scan events was preset at a value of 25%. All MS/MS data were
identified using SEQUEST (v.28, Bioworks 3.3 software package,
Thermo Electron) against the Human International Protein Index
(IPI) database (IPI human v3.45 FASTA with 71983 entries). The
search results were checked by examination of the Xcorr (cross-
correlation) and the DCn (delta normalized correlation) scores. In this
s t u d y ,a nX c o r rv a l u eo fg r e a t e rt h a n1 . 5 ,2 . 0 ,a n d2 . 5 ,r e s p e c t i v e l y ,f o r
1, 2, and 3 charged peptides and a DCn greater than 0.1 were
accepted as positive identification [28]. These peptides were converted
into a gene symbol and rearranged according to GO functional
enrichment provided by DAVID website. Then, ‘‘tetraspanin web’’
centered on CD151 was organized by the cytoscape (Ver: 2.6.2,
http://www.cytoscape.org/), a package to build network, searching
target genes that interacted with CD151 and removing the genes that
were not contained in our target genes using data source (NCBI
Entrez EUtilities WebS e r v i c eC l i e n t ) .
Transfection of lentiviral vectors CD151 or integrin b1
shRNA
The pGCSIL-GFP-shRNA-CD151 [8] and pGCSIL-GFP-
shRNA-integrin b1 were constructed (pGCSIL, a lentiviral vector,
Shanghai GeneChem Co. Ltd); pGCSIL-GFP was used as a
negative control. The sequence of shRNA targeting integrin b1i s
as follows: 59-GACTGAGCATGATGAAAGT-39. The lentiviral
vectors and pHelper were co-transfected into 293T cells. Culture
supernatants were collected, concentrated, and used as virus
stocks. The lentivirus was transfected into HCCLM3 cells with a
multiplicity of infection (MOI) of 20–50 (optimal MOI, 30).
pcDNA3-CD151cDNA plasmids, kindly provided by Hansoo Lee
(Kangwon National University, Korea), were transfected into
HepG2 cells using a lentiviral vector as previously described [8].
Immunocytochemistry (ICC), confocal laser scanning
microscopy and flow cytometry
HCCLM3 cells were used to show the co-localization of CD151
and integrin b1. Monoclonal mouse anti-human CD151 (11G5a,
1:100; Serotec, OX5 1GE, UK) and monoclonal rabbit anti-
human integrin b1 antibody (EP1041Y, 1:250; abCAM, CA USA)
were used for fluorescence cytostaining as previously described [8].
The localization of CD151 and integrin b1 was detected by
confocal laser scanning microscopy (LSM510; Zeiss, Germany).
Anti-human integrin b1/FITC antibody (BD Pharmingen, CA,
USA) was used to investigate the expression of integrin b1i n
HCCLM3, MHCC97H, MHCC97L, PLC/PRF/5, Hep3B, and
HepG2 via flow cytometry using MoFlo (DakoCytomation, Fort
Collins, CO) [18]. Isotype-matched immunoglobulin G served as a
control. Propidium iodide (1 mg/ml, Sigma-Aldrich, MO, USA)
was added to exclude dead cells.
Immunoblotting and reverse transcription polymerase
chain reaction (RT-PCR)
Immunoblotting and RT-PCRwereused to detectthe expression
of CD151 and integrin b1 in HCCLM3, short hairpin RNA
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-HCCLM3, MHCC97H, MHCC97L, PLC/PRF/5, Hep3B cells,
HepG2-CD151 (HepG2-pcDNA3-CD151-cDNA), HepG2-Mock
(HepG2-pcDNA3), HepG2-CD151-shRNA-CD151 and HepG2-
CD151-shRNA-integrin b1 [19,42]. Mouse anti-human CD151
monoclonal antibody (11G5a, 1:200; Serotec, OX5 1GE, UK) and
monoclonal rabbit anti-human integrin b1 antibody (EP1041Y,
1:500; abCAM, CA, USA) were used for immunoblotting, and
glyceraldehyde-3-phosphatedehydrogenase(GAPDH,1:5000;Che-
micon, Billerica, MA, USA) was used as an internal control. Primers
of CD151 for RT-PCR analysis: 59-ACTTCATCCTGCTCCT-
CATCAT-39 and 59-TCCGTGTTCAGCTGCTGGTA-39;i n t e -
grin b1: 59-GCTAAAATGCTGGCACCCTAA-39 and 59-ATAG-
TGCTCCCCAATGAAAGTAGAGA-39;G A P D H :5 9-GGCAT-
CCTGGGCTACACTGA-39 and 59-GTGGTCGTTGAGGGCA-
ATG-39. The relative expression of messenger RNA (mRNA) was
analyzed by the comparative cycle threshold (Ct) method. GAPDH
was used as an internal standard. All experiments were performed in
triplicate.
Invasion assay, migration assay, and enzyme-linked
immunosorbent assay (ELISA)
Invasive ability of shRNA-CD151-HCCLM3, HCCLM3-Mock,
shRNA-integrin b1-HCCLM3, HepG2-CD151, HepG2-Mock,
HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-inte-
grin b1 cells were assayed as described elsewhere [19].
MigrationabilityofshRNA-CD151-HCCLM3,HCCLM3-Mock,
shRNA-integrin b1-HCCLM3, HepG2-CD151, HepG2-Mock,
HepG2-CD151-shRNA-CD151andHepG2-CD151-shRNA-integrin
b1 were detected as described elsewhere [43].
The concentrations of MMP9 and MMP2 in a conditioned
medium from shRNA-CD151-HCCLM3, HCCLM3-Mock,
shRNA-integrin b1-HCCLM3, HepG2-CD151, HepG2-Mock,
HepG2-CD151-shRNA-CD151andHepG2-CD151-shRNA-integrin
b1 were determined by ELISA with a human MMP9 ELISA kit (R&D
Systems) and a human MMP2 ELISA kit (R&D Systems) respectively,
essentially as described previously [19]. All experiments were per-
formed in triplicate.
Metastasis assay
Metastasis nude model of shRNA-CD151-HCCLM3, HCCLM3-
Mock,shRNA-integrinb1-HCCLM3,HepG2-CD151,HepG2-Mock
cells, HepG2-CD151-shRNA-CD151 and HepG2-CD151-shRNA-
integrin b1 was constructed [44]. Serial sections were made for every
tissue block from the lung, and the total number of lung metastases was
counted under the microscope as described previously [18]. Each
g r o u pi n c l u d e df i v ea n i m a l s .
Patients and follow-up
Tumor specimens taken from areas next to the margin of tumors
were obtained from 301 consecutive patients who underwent curative
liver resection between 1997 and 2000 in Zhongshan Hospital of
Fudan University. Curative resection was defined as complete
resection of all tumor nodules and the cut surface being free of
cancer by histologic examination; having no cancerous thrombus in
the portal vein (main trunk or two major branches), hepatic veins, or
bile duct, and having no extrahepatic metastasis [19]. HCC diagnosis
was based on the World Health Organization criteria. Tumor
differentiation was defined according to the Edmondson grading
system [45]. Liver function was assessed by Child-Pugh score system.
Tumor staging was determined according to the sixth edition of
tumor node metastasis classification of Union Internationale Contre
le Cancer. Detailed clinicopathological characteristics were listed in
Table 2. Ethical approval was obtained from the research ethics
committee of Zhongshan Hospital, and written informed consent was
obtained from each patient. Follow-ups were terminated untilMarch,
2007. The median follow-up was 64 months (range, 4–121 months).
Follow up procedures were described in our previous study [19].
Treatment modalities after relapse were given according to uniform
guidelines as previously described [19].
Tissue microarray (TMA) and immunohistochemistry
TMA was constructed as described previously [19]. The mouse
anti-human CD151 (1:100, 11G5a, Serotec, OX5 1GE, UK) and
monoclonal rabbit anti-human integrin b1 antibody (EP1041Y,
1:250; abCAM) antibodies were used to detect the expression of
CD151 and integrin b1, respectively, based on a two-step protocol
as previously described [8]. The density of positive staining of
CD151 and integrin b1 was measured as described elsewhere [8].
Statistical analysis
Statistical analysis was done with SPSS software, version 12.0
(SPSS, Chicago, IL). Overall survival (OS) and time to recurrence
were defined as described previously [19]. The cumulative
recurrence and OS rates were calculated by the Kaplan-Meier
method and the log-rank test. Cox’s proportional hazards
regression model was used to analyze independent prognostic
factors. P,0.05 was set as the level of statistical significance.
Supporting Information
Figure S1 Expression of integrin a1, a2, a3, a6 and b1
mRNA in HCCLM3 cells. Expression of integrin a1, a2, a3, a6
and b1 mRNA in HCCLM3 cells was detected by qRT-PCR.
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